文献速递甲状腺疾病

美国基于前瞻性盲法研究:促甲状腺激素受体抗体在自身免疫性甲状腺疾病中的检测

US-based, Prospective, Blinded Study of Thyrotropin Receptor Antibody in Autoimmune Thyroid Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究在美国内分泌门诊前瞻性盲法比较4种促甲状腺激素受体抗体(TSH-R-Ab)检测的临床性能。162例连续入组甲状腺疾病患者及健康对照中,TSH-R-Ab结合法在无自身免疫性甲状腺疾病(AITD)者均为阴性;Graves病患者中TSI生物法阳性率87%高于Immulite法65%(P<.0025)和Cobas法63%(P<.0009)。结论认为结合法敏感性低于TSI生物法且不特异反映刺激性抗体。

要点

  • TSH-R-Ab结合法在42例无AITD者均阴性。
  • Graves病中TSI生物法阳性87例(84%),高于Immulite法65例(65%)和Cobas法63例(63%)。
  • 15例新诊断Graves病TSI法均阳性,结合法仅11例(73%)阳性。

核心结论

  • 结合法TSH-R-Ab检测敏感性低于TSI生物法,且不特异针对刺激性抗体。
  • 通过生物法测定TSH-R-Ab功能可为临床医生提供有用信息。

研究设计与样本

  • 美国基于内分泌门诊的前瞻性盲法研究,纳入162例未选择的连续、资料完整的各种甲状腺疾病患者及健康对照。
  • 对4种TSH-R-Ab检测进行盲法比较,主要结局为敏感性和特异性。

主要发现

  • 4种TSH-R-Ab检测在42例无自身免疫性甲状腺疾病(AITD)患者中均为阴性。
  • 104例Graves病患者中,无论病程长短,TSI生物法阳性87例(84%),Immulite结合法阳性67例(65%),Cobas结合法阳性65例(63%)(TSI vs Immulite P<.0025,TSI vs Cobas P<.0009)。
  • 15例新诊断Graves病患者TSI生物法均阳性,Cobas和Immulite结合法仅11例(73%)阳性。
  • 9例生化亚临床甲状腺功能亢进Graves病患者TSI阳性而Immulite和Cobas阴性。
  • 2例Graves病患者为阻断性TSH-R-Ab(TBI)阳性且TSI阴性,Immulite和Cobas均为阳性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Bioassays provide information on the functionality of thyrotropin receptor antibodies (TSH-R-Ab) and thus may offer more clinical utility than binding assays. OBJECTIVE: In this prospective, blinded, US-based study, the clinical performance of several TSH-R-Ab assays was compared. SETTING: US endocrinology clinic. SUBJECTS: One hundred sixty-two unselected, consecutive, well-documented patients with various thyroid diseases and healthy controls. INTERVENTION(S): Blinded TSH-R-Ab measurements. MAIN OUTCOME MEASURE(S): Sensitivity and specificity of 4 TSH-R-Ab assays. RESULTS: The 4 TSH-R-Ab assays were negative in all 42 patients without autoimmune thyroid disease (AITD). In 104 patients with Graves' disease (GD), irrespective of the disease duration, TSH-R-Ab positivity was present in 65 (63%), 67 (65%), and 87 (84%) for the Cobas and Immulite binding assays and stimulatory TSH-R-Ab [thyroid-stimulating immunoglobin (TSI)] bioassay, respectively (TSI vs Immulite P < .0025, TSI vs Cobas P < .0009). Fifteen newly diagnosed GD patients were all positive in the TSI bioassay, but only 11 (73%) were positive in the Cobas and Immulite binding assays. Nine GD patients with biochemical subclinical hyperthyroidism were TSI-positive but Immulite- and Cobas-negative. Two GD patients were blocking TSH-R-Ab [thyroid-blocking immunoglobin (TBI)]-positive and TSI-negative, and the Immulite and Cobas were positive in both. Additional serum samples from AITD patients that consisted of 30 TBI-positive and 10 TSI-positive samples were blindly tested in the binding assays. Only 6 of the 10 TSI-positive samples were positive in both binding assays, and 30 and 28 of the TBI-positive samples were positive in the Cobas and Immulite assays, respectively. CONCLUSION: Binding TSH-R-Ab assays are less sensitive than TSI bioassays and are not specific for stimulating antibodies. Measuring the function of TSH-R-Ab in a bioassay can provide useful information to clinicians.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lupo MA, Olivo PD, Luffy M, et al. US-based, Prospective, Blinded Study of Thyrotropin Receptor Antibody in Autoimmune Thyroid Disease. J Clin Endocrinol Metab. 2025. PMID: 39028731. doi:10.1210/clinem/dgae448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。